D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
LGND holding history
Ligand Pharmaceuticals Inc in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LGND overviewAll 13F holders of LGNDFull Q2 2026 holdings
- Shares (Q2 2026)
- 56,515
- Value
- $17.9M
- % of portfolio
- <0.1%
- Quarters held
- 13
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 56,515 | $17.9M | <0.1% | −21,913−27.9% | Reduced | Holders |
| Q1 2026 | 78,428 | $15.7M | <0.1% | +41,877+114.6% | Added | Holders |
| Q4 2025 | 36,551 | $6.91M | <0.1% | +19,037+108.7% | Added | Holders |
| Q3 2025 | 17,514 | $3.10M | <0.1% | +10,363+144.9% | Added | Holders |
| Q2 2025 | 7,151 | $812.9K | <0.1% | +7,151 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −25,743−100.0% | Sold out | Holders |
| Q2 2024 | 25,743 | $2.17M | <0.1% | −36,849−58.9% | Reduced | Holders |
| Q1 2024 | 62,592 | $4.58M | <0.1% | −25,317−28.8% | Reduced | Holders |
| Q4 2023 | 87,909 | $6.28M | <0.1% | −17,812−16.8% | Reduced | Holders |
| Q3 2023 | 105,721 | $6.33M | <0.1% | +54,347+105.8% | Added | Holders |
| Q2 2023 | 51,374 | $3.70M | <0.1% | +2,037+4.1% | Added | Holders |
| Q1 2023 | 49,337 | $3.63M | <0.1% | −1,964−3.8% | Reduced | Holders |
| Q4 2022 | 51,301 | $3.43M | <0.1% | +51,301 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −6,377−100.0% | Sold out | Holders |
| Q1 2021 | 6,377 | $972.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.